C12Y 306/04
Acting on acid anhydrides
Official title: acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
C12Y306/04 (Acting on acid anhydrides) appears on 99 US grants and 215 published applications in this corpus.
Search patents in C12Y- Granted patents
- 99
- Published applications
- 215
- Assignees
- 140
- Inventors
- 487
- Latest grant
- 24 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 1 | 0 |
| 2005 | 1 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 4 |
| 2012 | 0 | 1 |
| 2013 | 0 | 3 |
| 2014 | 2 | 5 |
| 2015 | 4 | 11 |
| 2016 | 4 | 14 |
| 2017 | 8 | 12 |
| 2018 | 9 | 10 |
| 2019 | 7 | 13 |
| 2020 | 12 | 18 |
| 2021 | 13 | 24 |
| 2022 | 8 | 12 |
| 2023 | 6 | 23 |
| 2024 | 11 | 21 |
| 2025 | 11 | 28 |
| 2026 | 2 | 15 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Treatment of psoriasis with interferon induced Helicase C domain 1 (IFIH1) inhibitors24 Mar 2026US 12,584,174 B2Regeneron Pharmaceuticals, Inc.
- Mesophilic argonaute systems and uses thereof27 Jan 2026US 12,534,499 B2Intima Bioscience, Inc.
- Compositions and methods for dissolving protein aggregates7 Oct 2025US 12,435,109 B2Rjk Biopharma Ltd.
- Conserved region T cell vaccines for coronavirus and methods of use22 Jul 2025US 12,364,750 B1Beth Israel Deaconess Medical Center, Inc.
- Bromodomain inhibitors to target therapy-resistant cancer17 Jun 2025US 12,329,755 B2University of Tennessee Research Foundation
- Modified helicases1 Oct 2026US 2026/0297544 A1Oxford Nanopore Technologies PLC
- Fusion proteins for improved gene editing24 Sep 2026US 2026/0286397 A1New York Genome Center, Inc.
- Strand Displacement-Based Gene Editing Method and System and Use Thereof17 Sep 2026US 2026/0275310 A1
- Vps4b inhibitor for use in methods for the treatment of hrd cancer10 Sep 2026US 2026/0265756 A1Institut Curie
- Helicase-cytidine deaminase complexes and methods of use27 Aug 2026US 2026/0250655 A1Illumina, Inc.
Most cited
By later US patents
- Enzyme stalling method36US 10,221,450 B2Oxford Nanopore Technologies PLC · 2019
- Multipart reagents having increased avidity for polymerase binding31US 10,704,094 B1Element Biosciences, Inc. · 2020
- Multipart reagents having increased avidity for polymerase binding31US 10,982,280 B2Element Biosciences, Inc. · 2021
- Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)25US 10,286,052 B2Immatics Biotechnologies GmbH · 2019
- Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)24US 10,064,924 B2Immatics Biotechnologies GmbH · 2018